Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 6/2011

01-11-2011 | Clinical Investigation

Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion

Authors: Atsushi Hayashi, Tatsuya Yunoki, Akio Miyakoshi, Keiichi Mitarai, Takahiro Fujino, Shuichiro Yanagisawa

Published in: Japanese Journal of Ophthalmology | Issue 6/2011

Login to get access

Abstract

Purpose

To evaluate the effects of combined therapy of intravitreal injections of bevacizumab (IVB) and additional macular grid laser photocoagulation for recurrent macular edema in branch retinal vein occlusion (BRVO).

Methods

This was a retrospective interventional case series in which 44 eyes of 44 patients with macular edema due to BRVO were studied. The mean follow-up term was 77.2 ± 12.4 weeks. All patients underwent IVB as a primary therapy. After two to three IVB, 19 of the 44 eyes (43.2%) underwent laser photocoagulation in the macular edema area to prevent the recurrence of the edema. In the other 25 eyes (56.8%), macular edema was successfully treated with IVB only. Visual acuity and central macular thickness (CMT) were examined during the follow-up.

Results

The mean visual acuity and the mean CMT in both groups improved significantly after the IVB. Following macular grid laser photocoagulation for recurrent macular edema, the mean visual acuity was maintained for 24 weeks, however, the mean CMT increased significantly after 12 weeks.

Conclusions

Additional grid laser photocoagulation for recurrent macular edema in BRVO after IVB maintained mean visual acuity with limited effects on the further recurrence of macular edema.
Literature
1.
Phillips S, Fekrat S, Finkelstein D. Branch retinal vein occlusion. In: Ryan SJ, editor. Retina. 4th edn. Philadelphia: Elsevier Inc; 2006. p. 1349–54.
2.
Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111–31.PubMedCrossRef
3.
Gutman FA. Macular edema in branch retinal vein occlusion: prognosis and management. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83:488–95.PubMed
4.
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–82.
5.
Parodi MB, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1999;237:1024–7.CrossRef
6.
The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Arch Ophthalmol. 2009;127:1115–28.CrossRef
7.
Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoids macular edema in branch retinal vein occlusion. Retina. 2009;29:511–5.PubMedCrossRef
8.
Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 2009;29:1242–8.PubMedCrossRef
9.
Jaissle G, Leitritz M, Gelisken F, Zimssen F, Bartz-Schmidt KU, Szuman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:27–33.PubMedCrossRef
10.
Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Canton V, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusion. Retina. 2009;29:1396–403.PubMedCrossRef
11.
Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol. 2010;94:1052–6.PubMedCrossRef
12.
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.PubMedCrossRef
13.
Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256–61.PubMedCrossRef
14.
Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51:1606–8.PubMedCrossRef
15.
Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248:155–9.PubMedCrossRef
16.
Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435–40.PubMedCrossRef
17.
Arnarsson A, Stefansson E. Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2000;41:877–9.PubMed
18.
Bandello F, Lanzetta P, Menchini U. When and how to do a grid laser for diabetic macular edema. Doc Ophthalmol. 1999;97:415–9.PubMedCrossRef
19.
Prasad PS, Oliver SCN, Coffee RE, Hubschman JP, Schwartz SD. Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology. 2010;117:780–4.PubMedCrossRef
20.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, OZURDEX GENEVA Study Group, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–46.PubMedCrossRef
Metadata
Title
Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion
Authors
Atsushi Hayashi
Tatsuya Yunoki
Akio Miyakoshi
Keiichi Mitarai
Takahiro Fujino
Shuichiro Yanagisawa
Publication date
01-11-2011
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 6/2011
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-011-0087-2

Other articles of this Issue 6/2011

Japanese Journal of Ophthalmology 6/2011 Go to the issue

Letter

A case of developmental glaucoma suspected from megalophthalmos represented by obstetric ultrasonography

Clinical Investigation

Correlation between cross-sectional shape of choroidal veins and choroidal thickness

Letter

Bilateral circumscribed choroidal hemangioma with retinal and choroidal venous abnormalities

Clinical Investigation

Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less

Scientific Reviewers

Scientific Reviewer

Laboratory Investigation

Hyaluronan production and hyaluronan synthase expression in three human conjunctiva-derived cell strains